Clinical Trial Update: An Explorative Study of HRS-2189 Combined With Adebrelimab and BP102 for Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 exploratory trial evaluating the combination of HRS-2189, Adebrelimab, and BP102 in metastatic colorectal cancer, currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Adebrelimab (adebrelimab)
• BP102
• HRS-2189

Snippet

Sponsor: Fudan University | Conditions: Colorectal Cancer Metastatic | Phase 2 | Status: NOT_YET_RECRUITING